Vertex Pharmaceuticals holds the cleaner structural position, with the lead spread across profitability and valuation. Edwards Lifesciences still has the edge on growth, which keeps the comparison from looking entirely one-sided. The market setup is currently leaning toward Edwards Lifesciences, which does not confirm the structural lead. That leaves a split case: the structural lead stays with Vertex Pharmaceuticals, but the market is not currently confirming it.
The comparison is based on similar long-term financial trajectories, not sector labels. Both peer scores are relative to the S&P 500 universe, making them directly comparable.
The lead is spread across profitability and valuation, rather than sitting in one isolated gap. Vertex Pharmaceuticals Incorporated leads by 19 points on the overall comparison score.
This comparison is anchored in long-term financial trajectory similarity within the selected peer universe.
The pair shares a valid long-term profile match, but the trajectories are not especially close.
Most of the shared profile comes through revenue stability and investment intensity.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
The largest gaps do not all point in the same direction.
Left means cheaper relative valuation. Higher means stronger structure.
Vertex Pharmaceuticals Incorporated looks stronger on relative valuation, while the broader price setup remains mixed.
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
Where EW and VRTX each sit in their own 5-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
The profitability lead is mainly driven by a 6.9-point operating margin advantage.
Growth still leans toward Edwards Lifesciences Corporation, so the lead is real without reading as one-way.
The lead is built on both profitability and valuation — though growth still provides a counterweight.
Break down the EW vs VRTX comparison across all dimensions with the full interactive tool.
Explore how EW and VRTX each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.